WR2721 as a modulator of cisplatin-and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach

Cancer Chemotherapy and Pharmacology

Volumn 33, Issue 2, 1993, Pages 93-106

  Treskes, Marco ^a   van der Vijgh, Wim J F ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 4 (METHYLSULFONYL)BUTYRYLGLUTAMYLHISTIDYLPHENYLALANYL DEXTRO LYSYLPHENYLALANINE; AMIFOSTINE; CARBOPLATIN; CISPLATIN; DIETHYLDITHIOCARBAMIC ACID; PROTECTIVE AGENT;

CANCER; CANCER CHEMOTHERAPY; CHEMOPROPHYLAXIS; NEPHROTOXICITY; NEUROTOXICITY; OTOTOXICITY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; VOMITING;

AMIFOSTINE; ANIMAL; BONE MARROW DISEASES; CARBOPLATIN; CISPLATIN; EAR DISEASES; GASTROINTESTINAL DISEASES; HUMAN; KIDNEY FAILURE, CHRONIC; NERVOUS SYSTEM DISEASES;

EID: 0027517584     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/BF00685326     Document Type: Review

References (196)

1. Sodium thiosulphate fails to increase the therapeutic index of intraveneously administered cis-diamminedichloroplatinum(II) in mice bearing murine and human tumors
2. Two-route chemotherapy using intra-arterial cisplatin and intravenous sodium thiosulphate, its neutralizing agent, for hepatic malignancies
3. Inactivation of cis-diamminedichloroplatinum(II) in blood by sodium thiosulphate
4. Two-route chemotherapy using cisplatin and its neutralizing agent, sodium thiosulphate, for intraperitoneal cancer
5. Protective effect of sodium 2-mercaptoethanesulfonate on the gastrointestinal toxicity and lethality of cis-diamminedichloro-platinum(II)
6. Protection against cisplatin toxicity by administration of glutathione ester
7. Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance
8. Selenium-induced protection against cis-diamminedichloroplatinum(II) diamminedichloroplatinum(II) nephrotoxicity in mice and rats
9. Selective reduction of cis-diamminedichloroplatinum(II) nephrotoxicity by ebselen
10. Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia
11. Dithiocarbamate-induced biliary platinum excretion and the control of cis-platinum nephrotoxicity
12. l-Methionine suppresses pathological sequelae of cis-platinum in the rat
13. l-Methionine antagonism of cis-platinum nephrotoxicity
14. Modification of cisplatin toxicity with diethyldithiocarbamate
15. Protective effect of organic cation transport inhibitors on cis-diamminedichloroplatinum-induced nephrotoxicity
16. Effect of dithiocarbamate on cis-diamminedi-chloroplatinum(II)-induced cytotoxicity, DNA cross-linking, and y-glutamyl transpeptidase inhibition
17. Selective protection against cis-diamminedichloroplatinum(II)-induced toxicity in kidney, gut, and bone marrow by diethyldithiocarbamate
18. Regeneration experiments of the platinated enzyme fumarase by sodium diethyldithiocarbamate, thiourea and sodium thiosulphate
19. The role of metallothionein in the reduction of cisplatin-induced nephrotoxicity by Bi3+-pretreatment in the rat in vivo and in vitro
20. Cisplatin-induced neuropathy: central, peripheral and autonomic nerve involvement
21. Cisplatin-induced changes in cytochrome P-450, lipid peroxidation and drug-metabolizing activities in rat kidney cortex
22. Biochemical modulation of cisplatin toxicity
23. Inhibition of cis-platinum nephrotoxicity by diethyldithiocarbamate in a rat model
24. Effect of diethyldithiocarbamate on tumor response to cis-platinum in a rat model
25. Biophysical studies of the modification of DNA by antitumour platinum coordination complexes
26. Mitochondrial injury: an early event in cisplatin toxicity to renal proximal tubules
27. Can WR2721 be improved upon?
28. o-(B-Hydroxyethyl)-rutoside-mediated protection of renal injury associated with cis-diamminedichloroplatinum(II)/hyperthermia treatment
29. Uptake of WR2721 derivatives by cells in culture: identification of the transported form of the drug
30. Evaluation of cis-diamminedichloroplatinum(II) combined with metoclopramide or sodium thiosulphate on L1210 leukemia in vitro and in vivo
31. The mechanism of renal clearance of cisplatin (cis-diamminedichloroplatinum II) and its modification by furosemide and probenecid
32. Cisplatin metabolites in plasma: a study of their pharmacokinetics and importance in the nephrotoxic and antitumour activity of cisplatin
33. Enhancement of cisplatin nephrotoxicity by probenecid
34. Cisplatin nephrotoxicity
35. Characterization of the reactions of platinum antitumor agents with biologic and nonbiologic sulphurcontaining nucleophiles
36. High-dose cisplatin with diethyldithiocarbamate (DDTC) rescue therapy: preliminary pharmacologic observations
37. Effects of nifedipine on cisplatinum-induced nephrotoxicity in rats
38. Stimulation of the renal endoplasmic reticulum calcium pump: a possible biomarker for platinate toxicity
39. The effect of diethyldithiocarbamate on the haematological toxicity and antitumour activity of carboplatin
40. Efficacy and safety of high-dose cisplatin and cyclophosphamide with glutathione protection in the treatment of bulky advanced epithelial ovarian cancer
41. Protective effects of O-(b-hydroxyethyl)-rutoside on cis-platinum-induced acute renal failure in the rat
42. Requirement of a reactive aldehyde moiety for aldehyde-mediated protection against cis-diamminedichloroplatinum(II)-induced cell inactivation
43. Cimetidine enhances cisplatin toxicity in mice
44. Experimental basis for increasing the therapeutic index of carboplatin in brain tumor therapy by pretreatment with WR-compounds
45. Mechanisms of resistance to platinum drugs
46. Interaction of cisplatin and carboplatin with sodium thiosulphate: reaction rates and protein binding
47. Modification of the bone marrow toxicity of cis-diamminedichloroplatinum(II) in mice by diethyldithiocarbamate
48. Effects of cisplatinum on metallothionein levels in mouse liver and kidney and in L1210 and L1210/PDD cell lines
49. Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification and quantiation
50. Platinum concentrations and DNA-adductlevels in tumors and organs of cisplatin-treated LOU/M rats inoculated with cisplatin-sensitive or-resistant immunoglobulin M immunocytoma
51. Kinetics of the formation and removal of cisplatin-DNA adducts in human blood cells and tumor tissue of cancer patients receiving chemotherapy: comparison with in vitro adduct formation
52. High-dose cisplatin in hypertonic saline: reduced toxicity of a modified dose schedule and correlation with plasma pharmacokinetics. A Northern California Oncology Group pilot study in non-small cell lung cancer
53. The in vitro effect of recombinant erythropoietin on cis-diamminedichloroplatinum-induced inhibition of murine erythroid stem cells
54. Effect of cisplatin on calcium uptake by rat kidney cortical mitochondria
55. Efficacy of the neuropeptide ORG.2766 in the prevention and treatment of cisplatin-induced neurotoxicity in rats
56. Prevention of cisplatin neurotoxicity with an ACTH(4–9) analogue in patients with ovarian cancer
57. Clinical trials of WR-2721 and cis-platinum
58. Effect of sodium thiosulphate on the pharmacokinetics, toxicity of cisplatin
59. Comparison of the pharmacokinetics of ultrafilterable cisplatin species detectable by derivatization with diethyldithiocarbamate or atomic absorption spectroscopy
60. Effects of diethyldithiocarbamate and nine other nucleophiles on the intersubunit protein cross-linking and inactivation of purified human α-macroglobulin by cis-diamminedichloroplatinum(II)
61. Mitochondrial alterations in cisplatin-induced acute renal failure
62. Diethyldithiocarbamate inhibition of murine bone marrow toxicity caused by cis-diamminedichloroplatinum(II) or diammine(1,1-cyclobutanedicarboxylato)platinum(II)
63. Prevention of renal toxicity of cisplatin by administration of bismuth subnitrate
64. How nephrotoxic is carboplatin?
65. Efficacy of two-route chemotherapy using cis-diamminedichloroplatinum(II) and its antidote, sodium thiosulphate, in combination with angiotensin II for rat liver tumor
66. Increased therapeutic effect on metastatic liver tumors in rats of two-route chemotherapy using cis-diamminedichloroplatinum(II) and its antidote, sodium thiosulphate, with temporary clamping of the abdominal aorta
67. Effect of aminophylline on cisplatin nephrotoxicity in the rat
68. Effects of sodium thiosulphate in combination therapy of cis-diamminedichloroplatinum and vindesine
69. Effect of sodium thiosulphate on cis-diamminedichloroplatinum(II) toxicity and antitumour activity in L1210 leukemia
70. Intraperitoneal cisplatin with systemic thiosulphate protection
71. Intraperitoneal cis-diamminedichloroplatinum(II) with systemic thiosulphate protection
72. Intraperitoneal cisplatin-based chemotherapy for ovarian carcinoma
73. Neutralizing effect of sodium thiosulphate on antitumour efficacy of cisplatin for human carcinoma xenografts in nude mice
74. Enhancement of cisplatin toxicity by buthionine sulfoxime, a glutathione-depleting agent, in mice
75. Two-route chemotherapy using high-dose i.p. cisplatin and i.v. sodium thiosulphate, its antidote, for peritoneally disseminated cancer in mice
76. Inactivation of cis-diamminedichloroplatinum(II) in blood and protection of its toxicity by sodium thiosulphate in rabbits
77. Inhibition of cis-diamminedichloroplatinum(II) secretion by the human kidney with probenecid
78. The use of probenecid as a chemoprotector against cisplatin nephrotoxicity
79. Control of nephrotoxicity in the rat during repeated cis-platinum treatments
80. Thiol and thioether suppression of cis-platinum-induced nephrotoxicity in rats bearing the Walker 256 carcinosarcoma
81. Modulation of cis-platinum renal toxicity by the radioprotective agent WR2721
82. Leukemia following chemotherapy for ovarian cancer
83. Nephrotoxicity and carcinogenic risk of cis-platin (cisplatin) prevented by sodium 2-mercaptoethanesulfonate (mesna): experimetal results
84. Protection against cis-diamminedichloroplatinum-induced nephrotoxicity in rats by N-benzyl- d-glucamine dithiocarbamate
85. Studies on the reaction products of cisplatin with sodium thiosulphate and their pharmacokinetic behavior in rabbits
86. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine(1,1-dicarboxylato-cyclobutane)platinum(II) differ only in the kinetics of their interaction with DNA
87. Systemic chemotherapy in tumor-bearing rats using high-dose cis-diamminedichloroplatinum(II) with low nephrotoxicity in combination with angiotensin II and sodium thiosulphate
88. Therapeutic efficacy of two-route chemotherapy using cis-diamminedichloroplatinum(II) and its antidote, sodium thiosulphate, combined with the angiotensin-II-induced hypertension method in rat uterine tumor
89. Protective effect of N-benzyl- d-glucamine dithiocarbamate against cis-diamminedichloroplatinum-induced toxicity in gastrointestinal tract and bone marrow in rats
90. Protection against cisplatin nephrotoxicity by prochlorperazine
91. Efficacy of two-route chemotherapy using cis-diamminedichloroplatinum(II) and its antidote, sodium thiosulphate, in combination with angiotensin II in a rat limb tumor
92. Clinical efficacy of two-route chemotherapy with cisplatin and thiosulphate for patients with peritonitis carcinomatosa
93. Reaction kinetics of cisplatin and its monoaquated species with the (potential) renal protecting agents (di)mesna and thiosulphate. Estimation of the effect of protecting agents on the plasma and peritoneal AUCs of cisplatin
94. Reversibility of binding of cisplatin-methionine in proteins by diethyldithiocarbamate or thiourea: a study with model adducts
95. Studies on hemotoxicity of cyclophosphamide, doxorubicin and cis-diamminedichloroplatinum(II) with sodium 2-mercaptoethane-sulfonate
96. Pharmacokinetics and disposition of WR-1065 in the rhesus monkey
97. Nephrotoxicity of high-dose intracavitary cisplatin with intravenous thiosulphate protection
98. High-dose intracavitary cisplatin with intravenous thiosulphate: low incidence of serious neurotoxicity
99. Phase-1 trial of high-dose intravenous cisplatin with simultaneous intravenous sodium thiosulphate
100. Improved use of buthionine sulfoximine to prevent cisplatin nephrotoxicity in rats
101. HPLC assay for 2-(3-aminopropyl)-ethanethiol (WR1065) in plasma
102. Mesna does not reduce cisplatin induced nephrotoxicity in the rat
103. Historical aspects of glutathione and cancer chemotherapy
104. Intracellular metabolites of cisplatin in the rat kidney
105. Quiescent LLC-PK1 cells as a model for cis-diamminedichloroplatinum(II) nephrotoxicity and modulation by thiol rescue agents
106. Role of endogenous sulfur-containing nucleophiles in an in vitro model of cis-diamminedichloroplatinum(II)-induced nephrotoxicity
107. A phase I trial of high-dose carboplatin + etoposide + dose escalation of cyclophosphamide with autologous bone marrow rescue in patients with refractory germ cell tumours
108. Introduction: cisplatin update
109. Morphological and electrophysiological study of the effects of cisplatin and ORG.2766 on rat spinal ganglion neurons
110. Enhanced therapeutic efficacy of cisplatin by combination with diethyldithiocarbamate and hyperthermia in a mouse model
111. Effect of selenite on renal toxicity and antitumor activity of cis-diamminedichloroplatinum(II) in mice inoculated with Ehrlich ascites tumor cell
112. Protective effect of metallothionein inducing metals on lethal toxicity of cis-diamminedichloroplatinum(II)
113. Prevention of lethal and renal toxicity of cis-diamminedichloroplatinum(II) by induction of metallothionein synthesis without compromising its antitumor activity in mice
114. Characteristics of inhibition of human renal adenosine triphosphatases by cisplatin and chloroplatinic acid
115. cis-Diamminedichloroplatinum(II)-induced sister chromatid exchanges and chromosome aberration formation in cultured human lymphocytes and their inhibition by sodium thiosulphate
116. The effects of co-administration of selenium on cisplatin-induced toxicity and antitumor activity
117. Reduced nephrotoxicity in vivo and in vitro of cisplatin-methionine complex
118. Amelioration of cisplatin-induced nephrotoxicity by the diuretic acetazolamide in F344 rats
119. Cisplatin dose intensity
120. Effect of diethyldithiocarbamate on toxicity of doxorubicin, cyclophosphamide and cis-diamminedichloroplatinum(II) on mice haemopoietic progenitor cells
121. Prospective randomized trial of high-dose cisplatin and fluorouracil infusion with or without sodium diethyldithiocarbamate in recurrent and/or metastatic squamous cell carcinoma of the head and neck
122. Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation
123. Platinum-DNA damage in leucocyte DNA of patients receiving cisplatin and carboplatin chemotherapy, measured by atomic absorption spectrometry
124. Effects of mannitol or furosemide diuresis on the nephrotoxicity and physiological disposition of cis-dichlorodiammineplatinum(II) in rats
125. Serotonin antagonists in the management of cisplatin-induced emesis
126. Resistance to alkylating agents and cisplatin: insights from ovarian carcinoma model systems
127. Phase I clinical and pharmacokinetic study of diethyldithiocarbamate as a chemoprotector from toxic effects of cisplatin
128. Quantitation of cis-diamminedichloroplatinum(II) (cisplatin)-DNA intrastrand adducts in testicular and ovarian cancer patients receiving cisplatin chemotherapy
129. Platinum-DNA adducts in leucocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy
130. The mechanism of action of platinum antitumor drugs
131. Effect of cis-diamminedichloroplatinum(II) on metallothionein induction and trace element metabolism in rats fed different amounts of dietary zinc
132. The prevention of cisplatin-induced renal dysfunction by hydroxyl-containing dithiocarbamates
133. Cisplatin
134. Platinum compounds: a new class of potent antitumour agents
135. High dose carboplatin with diethyldithiocarbamate chemoprotection in treatment of women with relapsed ovarian cancer
136. Cisplatin drug resistance
137. Cisplatin nephrotoxicity
138. Optimum schedule of selenium administration to reduce lethal and renal toxicities of cis-diamminedichloroplatinum(II) in mice
139. Molecular basis of cisplatin resistance in human carcinomas: model systems and patients
140. Diethyldithiocarbamate modulation of murine bone marrow toxicity induced by cis-diammine(cyclobutanedicarboxylato)platinum(II)
141. Mechanism of diethyldithiocarbamate modulation of murine bone marrow toxicity
142. Cisplatinum: effect of zine acetate pretreatment on cellular uptake and interactions with cytosolic ligands
143. Measurement of S-2-(3-aminopropyl-amino)ethanethiol (WR1065) in blood and tissue
144. WR2721 pharmacokinetics
145. Kinetics of thiosulphate, a cisplatin neutralizer
146. A phase I clinical and pharmacokinetic study of carboplatin and analogues: bone marrow support
147. The protective potential of the combination of verapamil and cimetidine on cisplatin-induced nephrotoxicity in man
148. Can bismuth decrease the kidney toxic effect of cis-platinum?
149. Stimulatory effect of cisplatin on production of lipid peroxidation in renal tissues
150. Adverse effects of antitumor drug cisplatin on rat kidney mitochondria: disturbances in glutathione peroxidase activity
151. The coordination chemistry of platinum anticancer drugs and related compounds with DNA
152. The interaction of cis-diamminedichloroplatinum(II) with metallothionein and glutathione in rat liver and kidney
153. Histopathological study regarding the protective effect of elastase on cis-platinum-induced renal toxicity
154. An improved HPLC assay for S-2-(3-aminopropyl)ethylphosphorothioate in plasma
155. Measurement of WR-1065 in plasma: preliminary pharmacokinetics in the beagle
156. A method for the combined measurement of ethiofos and WR-1065 in plasma: application to pharmacokinetic experiments with ethiofos and its metabolites
157. Two route chemotherapy by CDDP and STS against liver tumor
158. Antitumor activity and toxicity of serum-protein-bound platinum formed from cisplatin
159. Two-route chemotherapy with cisplatin (i.p.) and its antidote sodium thiosulphate (i.v.) against carcinomatous peritonitis following alimentary tract cancers
160. The hypertensive effect induced with angiotensin II and the physiological and pharmacokinetic aspects of two-route chemotherapy using cisplatin and STS
161. Characterization of cisplatin effects in the rabbit kidney and in renal proximal tubule cells in vitro
162. Immunocytochemical detection of interaction products of cis-diamminedichloroplatinum(II) and cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II) with DNA in rodent tissue sections
163. Monitoring of interaction products of cis-diamminedichloroplatinum(II) and cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II) with DNA in cells from cisplatin-treated cancer patients
164. Correlation between cell killing by cis-diamminedichloroplatinum(II) in six mammalian cell lines and binding of a cis-diamminedichloroplatinum(II)-DNA antiserum
165. Formation of interaction products of carboplatin with DNA in vitro and in cancer patients
166. Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies
167. The chemical reactivity of the modulating agent WR2721 (ethiofos) and its main metabolites with the antitumor agents cisplatin and carboplatin
168. Effects of the modulating agent WR2721 and its main metabolites on the formation and stability of cisplatin/DNA adducts in vitro
169. Reversal of cisplatin-protein interactions by WR2721 and its main metabolites WR1065 and WR33278
170. Cytostatic activity of cisplatin in the presence of WR2721 and its thiol metabolite WR1065 in OVCAR03 human ovarian cancer cells as compared to V79 fibroblasts
171. Time dependence of the selective modulation of cisplatin-induced nephrotoxicity by WR2721 (ethiofos) in the mouse
172. The effect of cisplatin on renal ATPase activity in vivo and in vitro
173. Effectiveness of two-route chemotherapy using cisplatin and its antidote, sodium thiosulphate, on lifespan of rats bearing metastatic liver tumors
174. Sodium thiosulphate inhibits cis-diamminedichloroplatinum(II) activity
175. Pharmacokinetics of WR-1065 in mouse tissue following treatment with WR-2721
176. Clinical pharmacokinetics of carboplatin
177. A randomized phase II study of cisplatin alone versus cisplatin plus disulfiram
178. Gastrointestinal toxicity of cis-diamminedichloroplatinum(II): a review
179. Ototoxicity of cis-diamminedichloroplatinum(II): influence of dose, schedule and mode of administration
180. Toxic effects of cis-diamminedichloroplatinum(II) in man
181. Carboplatin A preliminary review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in the treatment of cancer
182. Combination and individual antitumor effects of hyperthermia, cisplatin, and selected dithiocarbamates
183. The protective effect of selenite on cisplatin nephrotoxicity
184. Differential protection against cytotoxic chemotherapeutic effects on bone marrow CFUs by WR-2721
185. Mechanisms of cisplatin nephrotoxicity
186. Exacerbation of cisplatin-induced nephrotoxicity by methionine
187. Selective inhibition of the nephrotoxicity of cis-diamminedichloroplatinum(II) by WR-2721 without altering its antitumor properties
188. Treatment of tumours with the combination of WR-2721 and cis-diamminedichloroplatinum(II) or cyclophosphamide
189. Formation and repair of cisplatin lesions in specific genes in cisplatin sensitive and resistant human ovarian cancer cell lines
190. Protection against cisplatin-induced lipid peroxidation and kidney damage by procaine in rats
191. Protective effect of reduced glutathione against cisplatin-induced renal and systemic toxicity and its influence on the therapeutic activity of the antitumor drug